In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

AstraZeneca’s Net Zero Ambitions Factor In AI, Green Gas And Renewables

Biopharma’s Global Reforestation Plans Underline Its 'E in ESG' Credentials

Executive Summary

AstraZeneca was among the first seven companies globally to have its net zero targets verified by the Science-Based Targets initiative’s corporate net zero standard. Investment in green gas, reforestation and the associated use of AI mark the company out as a thought leader in sustainability initiatives. In this context, COP28’s renewed focus on ‘climate+health’ is well timed.

You may also be interested in...



The E in ESG: Philips Drives For Science-Based Targets In Carbon Zero Challenge

With a product mix that includes high energy consumption imaging, capital equipment and personal health care, Philips has a unique spectrum of challenges in driving low carbon health care. Nevertheless, it has set the bar high in environmental sustainability goals, and is pressing suppliers to follow its lead.

Medtech’s Role In The Carbon Neutral Challenge To Counter Climate Change – The UK View

“Sustainability executive” is a new job role for a new era. The UK’s largest healthtech industry association has appointed one, and many medtech companies in every geography might eventually do likewise, as the drive for nations to achieve carbon neutrality picks up pace. Medtech Insight spoke to the ABHI’s new incumbent Addie MacGregor and director of value and access Luella Trickett to gauge the size of the task before the medtech industry.    

CMS Incubator Helps ‘equIP’ Health Care Innovators With AI Power

The trend among device innovators to focus on diagnostic technologies that improve imaging, offer better visualization of tissues and avoid the need for biopsies is well noted by full-service law firm CMS. Its equIP program supports many start-ups incorporating AI into products and development processes.

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

IV148682

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel